Nature Medicine, Published online: 15 September 2026; doi:10.1038/s41591-026-04610-4
Two early clinical studies of selective KRASG12D inhibitors show encouraging activity in advanced cancers with G12D mutations, signaling a transformative change in the treatment landscape for RAS-driven cancers with potential applications across tumor types and stages of disease.
